Short answer
Nuvation Bio Inc. (NUVB) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Nuvation Bio’s quarter ended September 30, 2026.
Nuvation Bio Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Nuvation Bio’s quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for financial results and operating updates
- Quarterly disclosure may affect valuation, cash runway, and expectations for clinical development કામગીરી
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $45.0M, up from $13.1M, driven by IBTROZI product revenue $27.5M and collaboration revenue $17.5M
- IBTROZI revenue grew 18% sequentially, with approximately 160 new patient starts despite a 15% market decline
- FDA label update reflects 49.7-month median response duration, strengthening IBTROZI’s first-line commercial positioning
- Safusidenib received FDA Fast Track Designation, supporting accelerated development across Phase 2 and Phase 3 glioma studies
- Cash, equivalents and marketable securities $663.4M, while Q3 net loss narrowed to $41.9M from $55.8M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nuvation Bio Inc. 8-K filings
Get the next NUVB 8-K as it lands
Follow NUVB for push alerts, or ask the research agent what this filing means.